Evidence
Orv Hetil. 2023 Aug 20;164(33):1294-1299. doi: 10.1556/650.2023.32834. Print 2023 Aug 20.
ABSTRACT
Today, non-alcoholic fatty liver disease is the most common chronic liver disease, yet there is no clearly accepted effective therapy. What is certain is that the number of people suffering from the disease is increasing, making prevention, treatment and recognition of co-morbidities of paramount importance. Current evidence suggests that the development of non-alcoholic fatty liver disease may be due to pathological factors of different origins. The main risk factors include genetic factors, acquired environmental influences and lifestyle. Lifestyle modification, i.e., the elimination or reduction of these harmful factors, can reverse liver damage, depending on the stage of the disease. In this summary statement, we review the pathophysiology of non-alcoholic fatty liver disease, risk factors and therapeutic options, within that in particular lifestyle modification (dietary changes, increasing physical activity, weight loss). Furthermore, we also show the importance of omega-3 fatty acids such as eicosapentaenoic acid and docosahexaenoic acid in detail. With our knowledge, the personalized treatment of non-alcoholic fatty liver disease can be elaborated. Orv Hetil. 2023; 164(33): 1294-1299.
PMID:37598365 | DOI:10.1556/650.2023.32834
Add to Google Keep
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Real-Time Evidence Search [Psychiatry]
AI Search [Andisearch.com]
AI Q/A [Aikko.com]
The significance of omega-3 fatty acids in the treatment of non-alcoholic fatty liver disease
🌐 90 Days
VR Related Evidence Matrix
- Increasing the efficiency of hypolipidemic therapy with the combined use of quercetin in patients with non-alcoholic fatty liver disease on the background of the metabolic syndrome
- Chronic liver disease and management with silymarin: an introductory review of a clinical case collection
- Enhanced non-alcoholic fatty liver detection: Computed tomography scan image analysis and noise reduction with morphological dilation
- Research progress in the regulation of pathogenesis and the transformation of chronic liver disease by short-chain fatty acids
- Diabetes Mellitus among Patients with Non-alcoholic Fatty Liver Disease Visiting the Outpatient Department of Internal Medicine in a Tertiary Care Centre
- Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches
- Increased Risk of Colorectal Adenomas with Metabolic-Associated Fatty Liver Disease Components
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
- Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease
- Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
- The role of Sirtuin 2 in liver - An extensive and complex biological process
- The therapeutic mechanisms and beneficial effects of ursodeoxycholic acid in the treatment of nonalcoholic fatty liver disease: a systematic review
- The outcomes of nutritional therapy in patients with non-alcoholic fatty liver disease (NAFLD): Pitfalls in getting fit from fat
- Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies
- Immunology of gut microbiome and liver in non-alcoholic fatty liver disease (NAFLD): mechanisms, bacteria, and novel therapeutic targets
- Targeting metabolic-associated fatty liver disease in diabetic kidney disease: A call to action
- Sirt6 ablation in the liver causes fatty liver that increases cancer risky by upregulating Serpina12
- Sirt6 ablation in the liver causes fatty liver that increases cancer risky by upregulating Serpina12
- Therapeutic potential of oleanolic acid in liver diseases
- Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease
- A Review: Cytochrome P450 in Alcoholic and Non-Alcoholic Fatty Liver Disease
- Occult liver disease: a multinational perspective
- Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
- Exploring the interplay of gut microbiota, inflammation, and LDL-cholesterol: a multiomics Mendelian randomization analysis of their causal relationship in acute pancreatitis and non-alcoholic fatty liver disease
- Immunomodulation in non-alcoholic fatty liver disease: exploring mechanisms and applications
- Inflammatory liver diseases and susceptibility to sepsis
- Investigating the Role of Non-Coding RNA in Non-Alcoholic Fatty Liver Disease
- Epidemiological characteristics of inpatients with liver failure at the Beijing You'an Hospital from 2012 to 2021
- Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease
- Vitamin K2 protects mice against non-alcoholic fatty liver disease induced by high-fat diet
- Depression and hepatobiliary diseases: a bidirectional Mendelian randomization study
- Depression and hepatobiliary diseases: a bidirectional Mendelian randomization study
- Ultrasonographic findings of metabolic dysfunction-associated fatty liver disease: A comparative study with non-alcoholic fatty liver disease and clinical characteristics
- Review and expert opinion on MAFLD, oxidative stress and multifunctional management
- Healthy Lifestyle and the Risk of Metabolic Dysfunction-Associated Fatty Liver Disease: A Large Prospective Cohort Study
- Glycyrrhizin and the Related Preparations: An Inspiring Resource for the Treatment of Liver Diseases
- Impact of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) on the expression and function of hepatobiliary transporters: A comprehensive mechanistic review
- Therapeutic outcome of dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials
- Research progress on the mechanism of action of heme oxygenase-1 regulating ferroptosis in non-alcoholic fatty liver disease
- Determinants of non-alcoholic fatty liver disease in young people: Maternal, neonatal, and adolescent factors
- Natural compounds proposed for the management of non-alcoholic fatty liver disease
- Dysregulation of RNA splicing in early non-alcoholic fatty liver disease through hepatocellular carcinoma
- Fecal microbiota transplantation for treatment of non-alcoholic fatty liver disease: Mechanism, clinical evidence, and prospect
- Beneficial Effects of Dietary Flaxseed on Non-Alcoholic Fatty Liver Disease
- Liver Transplantation in Chronic Liver Disease and Acute on Chronic Liver Failure- Indication, Timing and Practices
- Liver Transplantation in Chronic Liver Disease and Acute on Chronic Liver Failure- Indication, Timing and Practices
- The Impact of Probiotic Bifidobacterium on Liver Diseases and the Microbiota
- Mass spectrometry imaging-based metabolomics highlights spatial metabolic alterations in three types of liver injuries
- Polysaccharide from Panax japonicus C.A. Mey prevents non-alcoholic fatty liver disease development based on regulating liver metabolism and gut microbiota in mice
- Interaction between fatty acid oxidation and ethanol metabolism in liver
- Adipose-derived extracellular vesicles - a novel cross-talk mechanism in insulin resistance, non-alcoholic fatty liver disease, and polycystic ovary syndrome
- Nonalcoholic Fatty Liver Disease and Continuous Metabolic Syndrome in Adolescents with Overweight/Obesity
- SHMT2 reduces fatty liver but is necessary for liver inflammation and fibrosis in mice
- SHMT2 reduces fatty liver but is necessary for liver inflammation and fibrosis in mice
- Metabolic Derangement in Non-Alcoholic Fatty Liver Disease: Opportunities for Early Diagnostic and Prognostic Markers
- Non-Alcoholic Fatty Liver Disease May Be a Risk Factor for Liver Metastasis After Radical Surgery for Colorectal Cancer: A Retrospective Study
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- Understanding the role of ursodeoxycholic acid and gut microbiome in non-alcoholic fatty liver disease: current evidence and perspectives
- COVID-19 in Individuals with Chronic Liver Diseases
- Plastic compounds and liver diseases: Whether bisphenol A is the only culprit
- Preventive hepatology at AIIMS Rishikesh: Delivering comprehensive and integrated care for liver diseases in Northern state of India
- Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study
Evidence Blueprint
The significance of omega-3 fatty acids in the treatment of non-alcoholic fatty liver disease
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
Save Evidence Blueprint
Save as PDF
The significance of omega-3 fatty acids in the treatment of non-alcoholic fatty liver disease
🌐 365 Days
VR Related Evidence Matrix
- Alcoholic liver disease - 2023
- Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases
- Barriers to lifestyle modification in patients with non-alcoholic fatty liver disease: a scoping review
- Progress in the Treatment of Metabolic-Related Fatty Liver Disease
- Association between the gut microbiota and nonalcoholic fatty liver disease: A two-sample Mendelian randomization study
- Serum Ferritin and Non-alcoholic Fatty Liver Disease: A Meta-analysis and Systematic Review
- Towards precision medicine in non-alcoholic fatty liver disease
- SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review
- How to identify at-risk NAFLD in the primary care setting
- Fatty liver disease's renaming impacts on drug clinical trials
- Non-alcoholic fatty liver disease and periodontal disease: A systematic review and meta-analysis of cross-sectional studies
- Research progress of celastrol on the prevention and treatment of metabolic associated fatty liver disease
- Increasing the efficiency of hypolipidemic therapy with the combined use of quercetin in patients with non-alcoholic fatty liver disease on the background of the metabolic syndrome
- Chronic liver disease and management with silymarin: an introductory review of a clinical case collection
- Enhanced non-alcoholic fatty liver detection: Computed tomography scan image analysis and noise reduction with morphological dilation
- Omega-3 intake is associated with liver disease protection
- The Prothrombotic Tendency of Metabolic-Associated Fatty Liver Disease
- Research progress in the regulation of pathogenesis and the transformation of chronic liver disease by short-chain fatty acids
- Diabetes and fatty liver: Involvement of incretin and its benefit for fatty liver management
- Diabetes Mellitus among Patients with Non-alcoholic Fatty Liver Disease Visiting the Outpatient Department of Internal Medicine in a Tertiary Care Centre
- Impact of Porphyromonas gingivalis-odontogenic infection on the pathogenesis of non-alcoholic fatty liver disease
- Large-scale metabolomic profiling and incident non-alcoholic fatty liver disease
- Hormone action and liver disease, a complex interplay
- New Insights into Nutrition and Gut-Liver Axis: A Focus on Non-Alcoholic Fatty Liver Disease
- Review of paediatric obesity and non-alcoholic fatty liver disease-A focus on emerging non-pharmacologic treatment strategies
- Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches
- Increased Risk of Colorectal Adenomas with Metabolic-Associated Fatty Liver Disease Components
- Non-alcoholic fatty liver disease-related hepatocellular carcinoma
- MBOAT7 in liver and extrahepatic diseases
- Therapeutic management of metabolic dysfunction associated steatotic liver disease
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- Anti-Angiogenic Effects of Natural Compounds in Diet-Associated Hepatic Inflammation
- Risk factors for macro vascular disease in type 2 diabetes mellitus patients with non-alcoholic fatty liver disease
- Diagnostic significance of alanine aminotransferase isoenzymes in alcoholic and non-alcoholic fatty liver cancers
- Association of thyroid disease and risk of fatty liver disease: an exposure-wide Mendelian randomization study
- Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
- From Non-Alcoholic Fatty Liver Disease to Liver Cancer: Microbiota and Inflammation as Key Players
- Metabolic dysfunction: The silenced connection with fatty liver disease
- MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
- Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease
- Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
- Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options
- Extracellular Vesicles and Fatty Liver
- Differences in Fecal Short-Chain Fatty Acids between Alcoholic Fatty Liver-Induced Cirrhosis and Non-alcoholic (Metabolic-Associated) Fatty Liver-Induced Cirrhosis
- Impact of Endoscopic Sleeve Gastroplasty in Non-alcoholic Fatty Liver Disease: a Systematic Review and Meta-analysis
- Diet and non-alcoholic fatty liver disease, a short narrative review
- Association of non-high-density lipoprotein cholesterol trajectories with the development of non-alcoholic fatty liver disease: an epidemiological and genome-wide association study
- Behaviour regulation and the role of mental health in non-alcoholic fatty liver disease
- Adherence to healthy lifestyle was associated with an attenuation of the risk of chronic kidney disease from metabolic dysfunction-associated fatty liver disease: Results from two prospective cohorts
- Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease
- Improvement situation on indexes of the zebrafish disease model of non-alcoholic fatty liver disease with FGF21 analogues
- The role of Sirtuin 2 in liver - An extensive and complex biological process
- NASH drug treatment development: challenges and lessons
- The therapeutic mechanisms and beneficial effects of ursodeoxycholic acid in the treatment of nonalcoholic fatty liver disease: a systematic review
- Sex, Nutrition, and NAFLD: Relevance of Environmental Pollution
- Endohepatology: The endoscopic armamentarium in the hand of the hepatologist
- Management of non-alcoholic fatty liver disease incidentally detected during other medical assessments
- Impact renaming non-alcoholic fatty liver disease to metabolic associated fatty liver disease in prevalence, characteristics and risk factors
- Challenges and Solutions in the Management of Hepatocellular Carcinoma Associated with Non-Alcoholic Fatty Liver Disease
- The outcomes of nutritional therapy in patients with non-alcoholic fatty liver disease (NAFLD): Pitfalls in getting fit from fat
- Impacts of gut microbiota alteration on age-related chronic liver diseases
- How non-alcoholic fatty liver disease and cirrhosis affect the heart
- Recent Advances in Mesenchymal Stem/Stromal Cell-Based Therapy for Alcohol-Associated Liver Disease and Non-alcoholic Fatty Liver Disease